Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

First CoreTherm® Eagle treatments performed in Denmark

ProstaLund

The first patients in Denmark with benign prostatic hyperplasia have now been successfully treated using ProstaLund’s new CoreTherm® Eagle. The treatments were carried out at Gentofte Hospital, marking the first clinic outside Sweden to adopt the new platform – a significant milestone in the international rollout.

“We are excited to see our first clinic outside Sweden now up and running with CoreTherm® Eagle. The successful treatments of the first patients in Denmark mark yet another important milestone in our continued rollout. Next step is to expand beyond the Nordic region, bringing the benefits of CoreTherm® Eagle to a broader international market,” says Malin Melander, acting CEO and COO at ProstaLund.

“We have now started treatment with the new CoreTherm® Eagle and everything has gone beyond expectations,” says Dr. Lilli Winck-Flyvholm, Senior Consultant in Urology at Gentofte Hospital.

CoreTherm® Eagle builds on more than 25 years of clinical experience from earlier CoreTherm® platforms, used in over 30,000 treatments for benign prostatic hyperplasia. The new platform includes major technical advancements, such as automated calculation of treatment goals and an improved user interface, providing increased support and ease of use for healthcare professionals.

For further information, please contact:


Malin Melander, acting CEO and Chief Operating Officer
Telefon: + 46 (0) 735 24 79 51
E-post: malin.melander@prostalund.com

About CoreTherm®


CoreTherm® is a minimally invasive transurethral microwave thermotherapy for benign prostatic enlargement (BPH). The treatment is performed in an outpatient setting under local anaesthesia and takes less than 15 minutes. No general anaesthesia or spinal block is needed. Follow-up data five years after CoreTherm® treatment shows clinical outcomes comparable to those seen after surgery/TURP (transurethral resection of the prostate), but with lower risk of serious complications. For more information visit, www.coretherm.com.

About ProstaLund


ProstaLund AB (publ) is a Swedish medtech company headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement (BPH). The company has patented the CoreTherm® Concept, a customised thermal treatment for BPE. ProstaLund is listed on Nasdaq First North Growth Market and has approximately 3,500 shareholders. For more information, visit www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

Attachments


First CoreTherm® Eagle treatments performed in Denmark

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.